2019-presentProfessor, School of Medicine, Tsinghua University
2018-presentPrincipal Investigator, Tsinghua-PKU, Center of Life Science
2017-2019Tenured Associate professor, School of Medicine, Tsinghua University
2014-2017Tenure-track Associate professor, School of Medicine, Tsinghua University
2010-2014Principal Investigator, School of Medicine, Tsinghua University
2007-2010Postdoctoral Fellow, Harvard-MIT Division of Health Science and Technology, MIT; Harvard Medical School, Harvard University, USA
2003-2007Ph.D. in Bioengineering, National University of Singapore, Singapore
1998-2002B.Eng. in Chemical Engineering, Tsinghua University, Beijing, China
We have been innovating in the field of ‘Microtissue Engineering’, with accomplishment in the theoretical elucidation and technological translation. Microtissue Engineering integrates biomaterials, microfabrication, biophysical and gene editing technologies to engineer and fine-tune the microscale 3D cell or tissue microenvironments, whichprovides innovative and effective tools and solutions for regenerative medicine, drug discovery and pathology study. We focus on1)establishment of stem cell microenvironment, immune cell microenvironment as well as fibrosis pathological microenvironments; 2)the mechanism investigation of cell-cell, cell-matrix interactions and3)their translational applications in regenerative medicine.
Specifically, through theconstruction of 3D stem cell micro-tissue, large-scale/high-quality in vitro stemcell manufacture and minimally invasive, targeted, efficient in vivo delivery andregeneration treatment have been accomplished; meanwhile, the 3D pathological micro-tissuearray technology realized high-throughput and accurate anti-fibrosis drugscreening and evaluation. The new pathological mechanism of cell mechanicalcommunication based on 'paratensile signaling' in the development of tissuefibrosis was discovered. 2patents of micro-tissue engineering have been commercially translated with relatedproducts approved as the first cell pharmaceutical excipients by both China CDE and US FDA.
.
Lab web:http://dulab-tsinghua.net/
1.Exendin-4 Gene-modification and Microscaffold Encapsulation Promote Self-persistence and Anti-diabetic Activity of MSCs,Science Advances, 2021, DOI: 10.1126/sciadv.abi4379
2.Matrix -transmitted paratensile signaling enables myofibroblast-1 fibroblast crosstalk in fibrosis expansion,PNAS, 2020, 03(27): 4-27
3.Cryoprotectant enables structural control of porous scaffolds for exploration of cellular mechano-responsiveness in 3D,Nature Communications, 2019, 10: 0-3491
4.Mechanotransduction-modulated fibrotic microniches reveal the contribution of angiogenesis in liver fibrosis,Nature Materials, 2017, 16(12): 1252-1261
5.Primed 3D injectable microniches enabling low-dosage cell therapy for critical limb ischemia,PNAS, 2014, 111(37): 13511-13516
学术荣誉与奖励
2021 国家自然科学基金“杰出青年”项目获得者
2018 北京自然科学基金“杰出青年”项目获得者
2017 教育部青年长江学者奖励计划
2015 国家自然科学基金“优秀青年”项目获得者
2014 清华大学“学术新人
